Tags

Type your tag names separated by a space and hit enter

Coeliac disease detection with an IgA/IgG-deamidated gliadin peptide based point of care test in community pharmacies.
Int J Clin Pharm. 2019 Apr; 41(2):583-588.IJ

Abstract

Background Coeliac disease affects 1% of the population, but 75% remain undiagnosed. Objective To conduct a case finding feasibility and efficacy study for the detection of coeliac disease in community pharmacies. Setting Six community pharmacies across Sheffield, UK. Method A prospective study was performed using a point of care test, Simtomax® (IgA/IgG-deamidated gliadin peptide) (C-test) in pharmacies. Pharmacy customers with symptoms suggestive of or risk factors for coeliac disease were tested with the C-test. Positive individuals were referred for a gastroscopy with duodenal biopsies alongside conventional serology. People with known coeliac disease, those on a gluten free diet or those who were investigated for coeliac disease were excluded. Main outcome measure The case detection rate and the uptake rate of the C-test and gastroscopies. Results Five-hundred participants fulfilled the inclusion criteria and were tested with the C-test (369 females, 73.8%; age range 18-87, median 49). The C-test uptake rate was 63%, and the positive rate was 7.2% (36/500). Twenty-seven positive participants (75%) underwent further investigations, confirming three new cases of coeliac disease (0.6%). Conclusion It was feasible to use the C-test as a case finding tool in pharmacies. There was good uptake for the C-test, although the case detection rate and the test specificity were low. Based on this, the C-test has a limited role in case finding in a community pharmacy setting.

Authors+Show Affiliations

Academic Department of Gastroenterology, Room P18, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, S10 2JF, UK. michellelau@doctors.org.uk.Academic Department of Gastroenterology, Room P18, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, S10 2JF, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30778740

Citation

Lau, Michelle S., and David S. Sanders. "Coeliac Disease Detection With an IgA/IgG-deamidated Gliadin Peptide Based Point of Care Test in Community Pharmacies." International Journal of Clinical Pharmacy, vol. 41, no. 2, 2019, pp. 583-588.
Lau MS, Sanders DS. Coeliac disease detection with an IgA/IgG-deamidated gliadin peptide based point of care test in community pharmacies. Int J Clin Pharm. 2019;41(2):583-588.
Lau, M. S., & Sanders, D. S. (2019). Coeliac disease detection with an IgA/IgG-deamidated gliadin peptide based point of care test in community pharmacies. International Journal of Clinical Pharmacy, 41(2), 583-588. https://doi.org/10.1007/s11096-019-00793-8
Lau MS, Sanders DS. Coeliac Disease Detection With an IgA/IgG-deamidated Gliadin Peptide Based Point of Care Test in Community Pharmacies. Int J Clin Pharm. 2019;41(2):583-588. PubMed PMID: 30778740.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coeliac disease detection with an IgA/IgG-deamidated gliadin peptide based point of care test in community pharmacies. AU - Lau,Michelle S, AU - Sanders,David S, Y1 - 2019/02/16/ PY - 2018/07/27/received PY - 2019/01/18/accepted PY - 2019/2/20/pubmed PY - 2019/11/19/medline PY - 2019/2/20/entrez KW - Case detection KW - Coeliac disease KW - Community pharmacy KW - DGP KW - Deaminated gliadin peptide KW - Point of care test KW - Primary care KW - Simtomax® SP - 583 EP - 588 JF - International journal of clinical pharmacy JO - Int J Clin Pharm VL - 41 IS - 2 N2 - Background Coeliac disease affects 1% of the population, but 75% remain undiagnosed. Objective To conduct a case finding feasibility and efficacy study for the detection of coeliac disease in community pharmacies. Setting Six community pharmacies across Sheffield, UK. Method A prospective study was performed using a point of care test, Simtomax® (IgA/IgG-deamidated gliadin peptide) (C-test) in pharmacies. Pharmacy customers with symptoms suggestive of or risk factors for coeliac disease were tested with the C-test. Positive individuals were referred for a gastroscopy with duodenal biopsies alongside conventional serology. People with known coeliac disease, those on a gluten free diet or those who were investigated for coeliac disease were excluded. Main outcome measure The case detection rate and the uptake rate of the C-test and gastroscopies. Results Five-hundred participants fulfilled the inclusion criteria and were tested with the C-test (369 females, 73.8%; age range 18-87, median 49). The C-test uptake rate was 63%, and the positive rate was 7.2% (36/500). Twenty-seven positive participants (75%) underwent further investigations, confirming three new cases of coeliac disease (0.6%). Conclusion It was feasible to use the C-test as a case finding tool in pharmacies. There was good uptake for the C-test, although the case detection rate and the test specificity were low. Based on this, the C-test has a limited role in case finding in a community pharmacy setting. SN - 2210-7711 UR - https://www.unboundmedicine.com/medline/citation/30778740/Coeliac_disease_detection_with_an_IgA/IgG_deamidated_gliadin_peptide_based_point_of_care_test_in_community_pharmacies_ L2 - https://dx.doi.org/10.1007/s11096-019-00793-8 DB - PRIME DP - Unbound Medicine ER -